Heart Health Showdown: Is Angioplasty or Bypass Better When Kidneys Are Struggling?
"New research dives deep into the best ways to keep your heart ticking when kidney disease complicates the picture."
When heart troubles and kidney problems team up, it's like navigating a maze with extra twists. Both conditions can worsen each other, making treatment choices a real head-scratcher for doctors and patients alike. Chronic kidney disease (CKD) throws a wrench into the works of stable coronary artery disease (CAD), demanding a closer look at how we manage heart health when kidneys aren't at their best.
For years, experts have been trying to nail down the safest, most effective ways to treat CAD in people with CKD. Should it be medication, a minimally invasive angioplasty, or open-heart bypass surgery? The answer isn't clear-cut, and solid research has been surprisingly scarce. This is particularly true when looking at the long-term effects of these treatments.
Now, a detailed study from the Medicine, Angioplasty, or Surgery Study II (MASS II) trial is shedding light on this complex issue. By tracking patients for a decade, researchers have uncovered critical insights into how different treatment strategies impact those with stable heart disease and varying degrees of kidney dysfunction. Let's break down what this means for you and your heart (and kidney) health.
CKD’s National Health Impact
The CDC’s March 2026 report provides updated national estimates of chronic kidney disease (CKD) and notes that CKD may lead to high blood pressure, heart disease, stroke, and early death. It also says people with CKD or at risk for it can take steps to protect their kidneys with help from health care providers. NIDDK, citing the CDC’s 2023 report, reports CKD in about 14% of non-Hispanic Black adults and 12% of non-Hispanic White adults.
Challenges in Combined Care
Heart failure (HF) and CKD frequently coexist, increasing the risks of hospitalization, disease progression, and death. A 2026 review says that despite advances in treating each condition independently, challenges remain in diagnosing and managing them together. A separate 2026 JACC abstract notes that real-world evidence on the sequence in which HF and CKD develop, and how that sequence affects use of HF guideline-directed medical therapy, is limited.
The Million-Dollar Question: How Do Heart Treatments Stack Up for Kidney Patients?
The MASS II trial sorted 611 patients into groups based on their kidney function, ranging from normal to mild or moderate CKD. These patients were then randomly assigned to one of three treatment paths: medication alone, angioplasty (PCI), or bypass surgery (CABG). The goal? To see which approach led to the best long-term outcomes, focusing on major events like death and heart attacks.
- Preserved Renal Function: eGFR ≥90 mL/min/1.73 m² (112 patients)
- Mild CKD: eGFR 89–60 mL/min/1.73 m² (349 patients)
- Moderate CKD: eGFR 59–30 mL/min/1.73 m² (150 patients)
Reviews of Kidney Disease and Heart Failure
Recent reviews examine the links between CKD and chronic HF, along with unmet needs in their treatment and management. One review outlines proposed pathological mechanisms connecting the conditions and emerging strategies to address those needs, including evaluation of kidney function in patients with HF. A KDIGO Controversies Conference held in March 2024 is noted in a 2026 review. Another review describes personalized medicine and novel therapies as promising, while emphasizing that ongoing research is needed.
Limits of the Evidence
Evidence comparing bypass surgery (CABG) with stenting (PCI) in people with CKD and complex coronary disease has important limitations. A systematic review notes that an earlier meta-analysis of non-randomized studies found a survival advantage for CABG over PCI in CKD with multivessel disease, but says unadjusted confounding factors affected those results. Another meta-analysis included 31 observational studies involving 74,805 patients and states that no randomized controlled trials had addressed the question. A further review included 24 retrospective or cohort studies, of which 9 used propensity matching.
A CKD Multivessel-Disease Comparison
In a study comparing drug-eluting stent PCI with CABG for multivessel disease in patients with CKD, the primary outcome occurred in 307 PCI patients (26.4%) and 304 CABG patients (32.2%). The adjusted hazard ratio was 0.941, with a 95% confidence interval of 0.79–1.12 and p=0.493. The reported figures do not establish a statistically significant difference in the primary outcome between the groups.
The Bottom Line: Taking Care of Your Heart and Kidneys
The MASS II trial gives us valuable insights: CAD linked with CKD leads to a worse outcome, whatever the treatment and interventional treatments like PCI or CABG seem to lower the rate of problems, compared to just sticking to medication, particularly for those with mild CKD. Remember, this is just one piece of the puzzle. The best path forward depends on your unique health profile. Working closely with your healthcare team is key to creating a treatment plan that protects both your heart and your kidneys.
Kidney and Heart Risks Together
A 2026 article reports that declining heart function can cause hemodynamic and metabolic changes that lead to acute and chronic kidney injury. It also says progressive sodium overload and fluid retention can trigger acute HF events. The article describes coexisting HF and CKD as negatively affecting short- and long-term cardiovascular outcomes.